Infectious Disease Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Department of Medicine, School of Medicine, College of Health Sciences, Makerere University and Mulago Hospital Complex, Kampala, Uganda.
PLoS One. 2018 Dec 31;13(12):e0209337. doi: 10.1371/journal.pone.0209337. eCollection 2018.
The mortality from cryptococcal meningitis remains high, despite the availability of antiretroviral therapy (ART) and amphotericin-based fungal regimens. The role of neutrophils in cryptococcosis is controversial. Our objective was to examine the association between blood neutrophil counts and outcomes in terms of mortality, the incidence of bacterial infections (including Mycobacterium tuberculosis) and hospitalization among HIV-infected patients presenting with cryptococcal meningitis.
We used data from participants from the Cryptococcal Optimal ART Timing (COAT) trial (2010-2012; Uganda and South Africa) and the Adjunctive Sertraline for Treatment of Cryptococcal Meningitis (ASTRO-CM) trial (2013-2017; Uganda). We estimated 30-day mortality risk with Cox proportional hazards models by baseline neutrophil counts (a) on a continuous scale and (b) with indicators for both relatively high (> 3,500 cells/mm3) and low (≤ 1,000 cells/mm3) counts. Follow-up neutrophil counts from the COAT trial were used to examine the time-dependent association of neutrophil counts with 12-month mortality and rehospitalization.
801 participants had an absolute neutrophil value at meningitis diagnosis. The median baseline absolute neutrophil count was 2100 cells/mm3 (IQR, 1400 to 3300 cells/mm3). Baseline neutrophil count was positively associated with 30-day mortality (adjusted hazard ratio = 1.09, 95%CI, 1.04-1.13, per 1000 cells/mm3 increase; p<0.001). Baseline absolute neutrophil counts ≤ 1000 cells/mm3 did not have increased risk of 30-day mortality compared to those with baseline neutrophils of 1001-3500 cells/mm3; however, baseline >3500 cells/mm3 had significantly increased risk, with an adjusted hazard ratio of 1.85(95%CI, 1.40-2.44; p<0.001). Among the COAT participants with follow-up neutrophil data, there was a strong association between time-updated neutrophil count and 12-month mortality (adjusted hazard ratio = 1.16, 95% CI 1.09-1.24; p<0.001.
Higher blood neutrophil counts in HIV-infected patients with cryptococcal meningitis were associated with mortality. Neutrophils role requires further investigation as to whether this may be a mediator directly contributing to mortality or merely a marker of underlying pathologies that increase mortality risk.
尽管有抗逆转录病毒疗法 (ART) 和两性霉素 B 为基础的真菌治疗方案,隐球菌性脑膜炎的死亡率仍然很高。中性粒细胞在隐球菌病中的作用存在争议。我们的目的是研究血液中性粒细胞计数与 HIV 感染患者出现隐球菌性脑膜炎的死亡率、细菌性感染(包括结核分枝杆菌)发生率和住院率之间的关系。
我们使用了来自 Cryptococcal Optimal ART Timing (COAT) 试验(2010-2012 年;乌干达和南非)和 Adjunctive Sertraline for Treatment of Cryptococcal Meningitis (ASTRO-CM) 试验(2013-2017 年;乌干达)参与者的数据。我们通过基线中性粒细胞计数(a)连续尺度和(b)相对高(>3500 个细胞/mm3)和低(≤1000 个细胞/mm3)计数的指标,使用 Cox 比例风险模型估计 30 天死亡率风险。COAT 试验的随访中性粒细胞计数用于检查中性粒细胞计数与 12 个月死亡率和再住院之间的时间依赖性关系。
801 名参与者在脑膜炎诊断时有绝对中性粒细胞值。中位基线绝对中性粒细胞计数为 2100 个细胞/mm3(IQR,1400-3300 个细胞/mm3)。基线中性粒细胞计数与 30 天死亡率呈正相关(调整后的危险比=1.09,95%CI,1.04-1.13,每增加 1000 个细胞/mm3;p<0.001)。与基线中性粒细胞为 1001-3500 个细胞/mm3 的患者相比,基线绝对中性粒细胞计数≤1000 个细胞/mm3 并没有增加 30 天死亡率的风险;然而,基线>3500 个细胞/mm3 具有显著增加的风险,调整后的危险比为 1.85(95%CI,1.40-2.44;p<0.001)。在有随访中性粒细胞数据的 COAT 参与者中,时间更新的中性粒细胞计数与 12 个月死亡率之间存在很强的关联(调整后的危险比=1.16,95%CI 1.09-1.24;p<0.001)。
HIV 感染的隐球菌性脑膜炎患者血液中性粒细胞计数较高与死亡率相关。中性粒细胞的作用需要进一步研究,以确定其是否是直接导致死亡率的介质,还是仅仅是增加死亡率风险的潜在病理的标志物。